Based on the close relationship between IR and the levels of inflammatory factors such as IL-6, a study on the IL-6 blocker tocilizumab found that intravenous administration of tocilizumab had a rapid positive effect on IR and insulin sensitivity in RA patients. This evidence concerns the gene IL6 and rheumatoid arthritis.